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Supplementary Methods I.  Reagent preparation and Bulk Cell Assay Protocols 
1. Synthesis of DNA-1o antibody conjugates  
As-received antibodies were desalted, buffer exchanged to pH 7.4 PBS and concentrated to 1 mg/mL 
using Zeba protein desalting spin columns (Pierce). Succinimidyl 4-hydrazinonicotinate acetone 
hydrazone (SANH, Solulink) in N,N-dimethylformamide (DMF) was added at a 150-fold molar excess to 
the antibodies. Separately, succinimidyl 4-formylbenzoate (SFB, Solulink) in DMF was added at a 20-fold 
molar excess to 5‘aminated 33 mer oligomers in PBS. After incubation for 4 h at room temperature, excess 
SANH and SFB were removed and both samples buffered exchanged to pH 6.0 citrate buffer using protein 
desalting spin columns. A 20-fold excess of derivatized DNA was then combined with the antibody and 
allowed to react 2 hr at room temperature. Noncoupled DNA was removed using a Pharmacia Superdex 
200 gel filtration column at 0.5 mL/min isocratic flow of PBS. The conjugates were then concentrated to 1 
mg/ml by Amicon Ultra-4 Centrifugal Filter Unit with Ultracel-10 membrane (Millipore, 10 kDa) and 
stored at 4oC. The conjugation yield was determined by Nanodrop (Thermal Scientific). Detailed protocol 
can be found in the Protein-Oligo Conjugation Kit (Solulink). The conjugates were then validated with 
standard proteins by DNA spot microarrays (Figure S6). See Supplementary Method 6 for details of 
conjugate validation.  
2. Western blot Assays    
    Western blotting was as previously described. Cultured cells in 60 mm dish were lysed and 
homogenized using buffer containing 10 mmol/L Tris, pH 7.4, 100 mmol/L NaCl, 1 mmol/L EDTA, 1 
mmol/L EGTA, 1 mmol/L NaF, 20 mmol/L Na4P2O7, 2 mmol/L Na3VO4, 0.1% sodium dodecyl sulfate, 
0.5% sodium deoxycholate, 1% Triton X-100, 10% glycerol, 10 µg/mL leupeptin, 60 µg/mL aprotinin, and 
1 mmol/L phenylmethanesulfonyl fluoride. Equal amounts of protein extracts were separated by using 8% 
or 10% SDS-PAGE, and then transferred to a polyvinylidene difluoride membrane (Bio-Rad Laboratories 
Inc, Hercules, CA). After blocking for 1 hour in a Tris-buffered saline containing 0.1% Tween 20 and 5% 
nonfat milk, the membrane was probed with various primary antibodies, followed by secondary antibodies 
conjugated to horseradish peroxidase. The immunoreactivity was revealed by use of an ECL kit 
(Amersham Biosciences Co, Piscataway, NJ). The antibodies were obtained from Cell Signaling (p-Erk 
Thr202/204, p-mTOR Ser2481, p-Src Tyr527, p-p70S6K Thr389, p-Akt Ser473, p-GSK3 Ser9, GSK3, 
phospho-EGFR), Sigma (α-actin) and Upstate (EGFR/EGFRvIII cocktail antibody). 
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3. DNA Spot microarrays for bulk protein measurements 
The DNA-1o antibody conjugate validation, check of cross-reactivity among antibodies and the 
measurement of EGFR phosphorylation states were performed on DNA spot microarrays printed by 
Institute of Systems Biology (Seattle, WA) using the same DNA oligos as those in microfluidic DNA 
barcode patterning.3 For device assembly, a 12-well PDMS slab was bonded to the glass slide with DNA 
spot microarrays, as shown in Figure S5. Each well contains repeated 13 DNA spot microarrays. The 
diameter of each spot is 150 μm, and distance between neighboring spots is 400 μm.  
1) Conjugate validation. a) Block each well with 1% BSA for 1 h. b) Add 50 μl of conjugate (5 μg/ml) 
into the well and incubate at room temperature for 1 h. c) Aspirate each well and wash with 1% BSA, 
repeating the process two times for a total of 3 washes. d) Add 50 μl of standard protein in PBS and 
incubate at room temperature for 1 h. Meanwhile, add 50 μl of PBS in another well as the negative 
control. e) Wash each well with 1% BSA for three times. f) Add 50 μl of biotin-labeled detection 
antibody and incubate at room temperature for 1 h. g) Wash each well with 1% BSA for three times. h) 
Add a mixture of Cy5 fluorescent dye-labeled streptavidin and Cy3-labeled reference complementary 
ssDNA and incubate at room temperature for 1 h. i) Wash each well with 1% BSA for three times and 
PBS for two times. j) The PDMS device is removed from the glass slide, and is immediately dipped 3 
times each in the following solutions in order, 1X PBS, 0.5X PBS, deionized Millipore H2O, and 
finally dried with a nitrogen gun. k) The slide was scanned by Axon GenePix 4400A. 5 μm of 
resolution is selected. Two color channels (the green Cy3 and the red Cy5 channel) are turned on to 
collect fluorescence signals.  
2) Cross-reactivity check of antibodies. The experimental procedure is similar with the conjugate 
validation. In order to validate the cross-reactivity of antibodies, all conjugates and detection 
antibodies are added in each well but only one standard protein is added in each well.  
3) Measurement of EGFR phosphorylation states. The experimental procedure is similar with the 
conjugate validation, excepting using cell lysate instead of standard protiens. The treated cells are 
washed with cold PBS to remove residual media. Cell lysis buffer (1X) is then added and the cells are 
incubated on ice for 10 minutes. The cell extract is then collected and spun at 14,000 g in a 
microcentrifuge at 4oC for 10 minutes, and the supernatant is removed for use. p-EGFR/ssDNA 
conjugates specific for phosphorylation of EGFR at Y1173, Y1068 and Y845 are used as capture 
antibodies and biotin-labeled EGFR is used as detection antibody.  
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Supplementary Methods II:   Single Cell Barcode Chip Fabrication & Operation 
1. DNA barcode array   
    This procedure has been previously described in detail (1), and so only a brief description is provided 
here. The PDMS elastomer-based microfluidic patterning chips were fabricated via a molding process 
from a silicon master with photolithographically-defined patterns. The mixture of GE RTV 615 PDMS 
prepolymer and curing agent (10:1) was stirred, and poured onto the silicon mold, which was pre-treated 
with trimethyl-chloro-silane (TMCS) vapor to facilitate mold release. The PDMS is then poured on the 
mold, degassed for 30 min (house vacuum), and then cured at 80oC for 1 h. The solidified PDMS slab was 
cut from the mold, assess holes drilled and then bonded onto a polylysine glass slide (VWR). The 
microfluidic patterning chip contained 13 parallel microchannels patterned such that they cover a large 
area (3cm×2cm) of the glass slide for creating the DNA barcode microarray. Each microchannel is 
approximately 0.5 meters long and 20 micrometers wide. 
    For creating a DNA barcode array pattern, multiple DNA solutions (one for each barcode stripe), are 
each diluted in a mixture of DMSO and deionized water (v/v=1:2) with a final DNA concentration of 267 
M. These solutions are each flowed into a specific microfluidic channel. The solution-filled chip was 
placed in a desiccator to allow solvent (DMSO and water) to evaporate completely through the 
gas-permeable PDMS, leaving the DNA molecules behind. This evaporation process took 3-5 days to 
complete. Last, the PDMS elastomer was removed from the glass slide, and the barcode-patterned DNA 
was fixed to the glass surface by thermal treatment at 80oC for 4 hours. Residue crystals were readily 
removed by rapidly dipping the slide in deionized water. Each DNA barcode chip needs validation before 
bonding to bonding the single cell assay chip. A small area near edge was validated to check the DNA 
loading and uniformity. It was blocked with 1% Bovine Serum Albumin (BSA)/PBS for 1 hr, and then 
hybridized with fluorescent Cy3-labeled complementary DNA for 1 hr. After washing three times with 1% 
BSA/PBS and PBS, the slide was dried by nitrogen gun and scanned by Axon GenePix 4400A . Under 
laser power of 15% and gain of 450, fluorescence intensity above 10,000 was acceptable for cytoplasmic 
protein detection at the single cell level.  
2. Single Cell Barcode Chip (SCBC) fabrication   
    The PDMS microfluidic chip for the cell experiment was fabricated by two-layer soft lithography 
(Fig. SM.II.1 A,B,C). A push-down valve configuration was utilized with a thick control layer bonded 
together with a thin flow layer. The molds for the control layer and the flow layer were fabricated with 
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SU8 2010 negative photoresist (~23 μm thickness) and SPR 220 positive photoresist (~15 μm), 
respectively. The photoresist patterns for the flow layer were rounded via thermal treatment. The thick 
control layer was molded with a 10:1 mixture of GE RTV 615 PDMS prepolymer part A and part B (w/w) 
and the flow layer was formed by spin-coating a 20:1 mixture of GE RTV 615 part A and part B (w/w) on 
the flow layer mold at 2000 rpm for 60 second. Both layers were cured at 80°C for 1 hour, whereupon the 
control layer was cut from its mold and aligned to the flow layer. An additional 60 minute of thermal 
 
Figure SM.II.1 Single Cell Barcode Chip Design and Operation. (A) Design of the SCBC microfluidic chip 
for on-chip cell lysis and multiplex phosphoprotein detection. V1 to V6 represent valves. V3 isolates 
chambers from channels and V4 controls the diffusion between acell chamber and a ysis buffer chamber. 
V1, V2, V5, and V6 control flow within the microchannels. (B, C) A single measurement unit of the SCBC. 
Single or few cells are isolated in the 2 nL microchamber. Intracellular proteins are assayed by 
introducing a pre-aliquoted lysis buffer, whereupon the released proteins bind to the antibody microarray 
barcode within the chamber. (D) Visualization of on-chip lysis buffer diffusion. Red food dye was used to 
visualize the diffusion process. The chip was sitting on the ice and tilted to accelerate on-chip diffusion.  
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treatment at 80°C ensured that the two layers bonded into a monolithic device, which was then peeled 
from its mold and punched to create appropriate access holes. Finally, the PDMS chip was thermally 
bonded to the microarray-patterned glass slide to form the working device.  
3. SCBC-assay protocols 
    The use of an SCBC was as follows:  
a) Blocking: All microfluidic channels were first blocked with the blocking buffer (3% w/v Bovine 
Serum Albumin + 0.1% N-Dodecyl--D-maltoside in 1X PBS) for 60 min. N-Dodecyl--D-maltoside was 
reported to minimize non-specific protein adsorption on PDMS. (2)  
b) Forming capture antibody microarrays: A solution containing all DNA-antibody conjugates was 
flowed through the assay channels of the SCBCs for 60 min, which transformed the DNA barcode 
microarrays into antibody microarrays enabling the subsequent surface-bound immuno-assay. The 
unbound conjugates were removed by flowing the washing buffer (3% BSA + 1% phosphatase inhibitor) 
for 10 min. The DNA-antibody conjugate solution (100 μl) was prepared by mixing all synthesized 
conjugates in 3% BSA with a final concentration of 10 μg/mL of each conjugate.  
c) On-chip cell lysis and intracellular protein measurement: The concentrated cell lysis buffer (4X) 
was prepared by mixing Cell Lysis Buffer (Cell Signaling, containing 20 mM Tris-HCl, 150 mM NaCl, 1 
mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM -glycerophosphate, 1 
mM Na3VO4, and 1 g/ml leupeptin), Complete Protease Inhibitor Cocktail (Roche) and Phosphatase 
Inhibitor Cocktail 2 (Sigma). This lysis buffer can efficiently extract nuclear, membrane associated, and 
cytoplasmic proteins. The lysis buffer was loaded into the lysis buffer chambers (Fig. SM.II.1 C) while the 
valve 4 (Fig. SM.II.1 A) was kept closed by applying 18-20 psi constant pressure. After cell treatment, the 
treated cells were dissociated with trypsin and EDTA, centrifuged at 4oC and suspended in cold PBS with 
a concentration of 1000 cell/μL. Then, cells were loaded into the pre-chilled microfluidic chips, and valve 
3 (Fig SM.II.1 A) were closed to compartmentalize cells, which converted the 8 channels into 120 isolated 
microchambers. The cells on the chip were recorded by a CCD camera for cell counting at 4oC. 
Subsequently, the chip was sitting on the ice and the valve 4 was opened for on-chip diffusion of lysis 
buffer to the neighboring cell chambers (Fig SM.II.1 D). The chip was tilted to accelerate the lysis buffer 
diffusion. After 20 minutes of lysis buffer diffusion and on-chip cell lysis, the valve 4 was closed and the 
chip was incubated on ice for 20 more minutes with shaking to complete the on-chip cell lysis. The chip 
was incubated at room temperature with shaking for 2 hours to allow capture of target proteins by 
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antibody microarrays within the microchambers. Afterwards, the unbound cell lysate was quickly removed 
by flowing the washing buffer for 10 min.  
d) Applying detection antibodies: A mixture of biotin-labeled detection antibodies was flowed into the 
SCBC for 60 min at room temperature to complete the DEAL assay. The detection antibody solution 
contained biotinylated detection antibodies at ~3 μg/mL (or specified in the insert of the ELISA kit; the 
concentration varies from lot to lot) prepared in washing buffer. Then, unbound detection antibodies in the 
SCBC were removed by flowing the washing buffer for 10 min.  
e) Fluoresence probes: Cy5 fluorescent dye-labeled streptavidin (eBioscience, 2 μg/mL) and the 
reference, Cy3-labeled complementary ssDNA (DNA code M/M’, 25 nM), were mixed together and were 
then flowed into the SCBC for 60 min. Afterwards, 3% BSA/PBS was flowed for 20 min to remove 
unbound Steptavidin-Cy5, and 1X Phosphate Buffered Saline Tween-20 (PBST) was flowed for 40 min as 
the final wash step.  
f) Rinse: The PDMS chip device was removed from the DNA-patterned glass slide, and was 
immediately dipped 3 times each in the following solutions in order, PBST, 1X PBS, 0.5X PBS, deionized 
Millipore H2O, and finally dried with a nitrogen gun.  
g) Optical readout: The slide was scanned by Axon GenePix 4400A (Molecular Devices). The finest 
resolution (2.5 μm) was selected. Two color channels (the green Cy3 and the red Cy5 channel) were 
turned on to collect fluorescence signals.  
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Supplementary Methods III:  Calibration Data and Analysis, Signal Variation, 
Experimental Error, and Biological Coefficient of Variation, in SCBC Assays 
In this paper, we report on the single cell fluctuations for specific proteins. These fluctuations may be 
represented as a histogram in which the recorded level of a protein is plotted versus the frequency of 
observation. This histogram may have a significant width, meaning that the recorded variations in protein 
level across all single cell assays span a large range. That width can arise from experimental measurement 
error, or it can arise from the stochastic nature of the cells. Here we present an analysis of this signal 
variation, and show that, in most cases, the width of the fluctuations, represented as a coefficient of 
variation, is dominated by the biology, rather than by the experiment.   
The experimental error is comprised of two contributions. One is the experimental uncertainty 
associated with the barcode structured protein assays. In Figure SM.III.1 C, histograms are provided for 
barcode assays of the proteins p-mTOR and p-p38, and the coefficient of variation (CV) of those 
histograms is ~8%. These histograms are generated from the calibration measurements that utilized the 
cocktail of recombinant proteins, and are representative of all of the proteins assayed here over a broad 
range of concentrations (Figure SM.III.1 B). In general, the CVs for all of the proteins, as assayed in this 
fashion, are <15%. This data is shown in Table SM.III.1.  
A second potential contribution to the experimental error is the location of a cell within a 
microchamber, relative to the barcode positions. This error arises because of competition between 
antibody/protein binding kinetics, and protein diffusion. Thus, if a cell is randomly placed within a 
microchamber, the barcode closest to that cell may record a relatively higher amount of protein. Since the 
cells are randomly distributed in the various chambers, this adds an error to the SCBC system. However, 
we can record the positions of the cells, as well as the fluorescence intensities from the duplicate barcode 
arrays, and so we can investigate whether this error is systematic. If it is systematic, then it can be 
accounted for, and its contribution to the experimental error subtracted.   
We thus examined the individual fluorescence signal intensities of the two barcodes within 
microchambers containing single cells, while also recording the position of the single cell. The intensity 
ratio of the two barcodes exhibited a clear linear dependence upon the location of the cell - the closer the 
cell is to one barcode, the more intense is that barcode fluorescence signal, while the more distant barcode 
signal is proportionately weaker (Figure SM.III.2 A). Thus data indicated that the measurement error that 
arises from cell location is indeed systematic, and can be accounted for. 
For evaluating this systematic error, a Monte Carlo simulation was carried out busing the R software 
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package (version 2.10.1; R Foundation for Statistical Computing©). This simulation should correctly 
capture the physics of the measurement, since the equations for protein diffusion are known exactly, and 
typical antibody/protein binding kinetics can also be accurately modeled as well. To investigate the 
importance of the cell location on signal variation, we assumed, for the simulation, that each single cell 
releases a fixed amount of specific protein. This assumption removes the effect of biological variation and 
allows us to focus on the measurement error. The parameters used in the simulation match our 
experimental environment. The chamber is 2000 µm in length and 100 µm wide, with two sets of DNA 
barcode M-A and A-M from left to right. Excluding the 200 µm wide valves at the microchamber ends, 
the effective length of the chamber is 1800 µm. Each barcode stripe is 20 µm wide, and the stripes are 
patterned at 50 m pitch. For the simulations, a single cell is randomly distributed in a chamber.   
Figure SM.III.2 B-D are the simulated distributions of fluorescence signal intensity per chamber for 
5000 single cell chambers with proteins conjugated by DNA barcode positions L, G and A respectively. 
The maximum protein intensity, which is assigned to the case for which a cell sits directly on a given 
barcode stripe, was set at 200. The measurement uncertainty for a given protein was set 10%, which is 
representative of the experimentally determined measurement uncertainties from the calibration data. The 
blue curves are Gaussian fitting with the sample average and sample standard deviation obtained from the 
simulation. The fits indicate that the average intensity per chamber follows a Gaussian distribution after 
including the randomness of cell locations. This is, then, the statistical distribution of our measurements 
for single cell chambers after accounting for the barcode measurement uncertainties, the uncertainties 
arising from cell locations, and the zero cell heterogeneity, i.e. the system error. 
Figure SM.III.2 E shows three representative microchambers generated from the simulation for 
barcode position ‘L’. The average protein intensity measured from in these chambers ranges from 161 to 
184, indicating that a similar averaged intensity (limited by the intrinsic barcode assay uncertainty) is 
measured, regardless of cell position.  
By using the detection error for a DNA barcode conjugated with a specific protein in Table SM.III.1, 
matching the concentration close to the actual level in the experiment, the Monte Carlo simulation can 
give out the system error of our measurement. Consequently, the single cell biological variation can be 
quantitatively estimated by the formula below: 
    biolobicalerimentAssay CVCVCV
2
exp
2                         (1) 
where the CVAssay refers to the total CV of our experiment data and CVexperiment is dominated by the 
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uncertainty estimated from the calibration data. An estimation of biological variation of U87 EGFR VIII is 
shown in Figure SM.III.2 F.  
 
Figure SM.III.1  Assay calibration & determination of assay error and assay cross-reactivity. (A) 
Fluorescence image of DNA barcode stripes across the surface of a chip, with an intensity histogram that 
shows that the coefficient of variation (CV) in the DNA pattern is <5%. An Axon GenePix 4400A (Molecular 
Devices) was used to obtained the fluorescence images in the 532 nm channel with a laser power set at 
15% and an optical gain of 450. (B) Fluorescence images used to extract calibration data for the SCBC 
assays, and representing a serial dilution of the SCBC assayed panel of proteins. These calibrations were 
performed under conditions identical to the single and few-cell assays, except that standard proteins were 
used, rather than cells. Standard proteins were serially diluted in 1X PBS and flowed into the SCBC 
microchannels. (C) Representative histograms of p-mTOR (1 ng/ml) and p-p38 (10 ng/ml) measurements, 
showing a coefficient of variation of ~8%. (D) Calibration curves for several assayed proteins. (E) Plot 
showing the relationship between on-chip incubation time and obtained intensity; only ~30 min is required 
to capture 90+% of released proteins such as p-Src and EGFR following cell lysis; 2 hr of incubation is 
sufficient to capture 95+% of the released proteins following cell lysis. (F) Cross-reactivity of panel of 
assayed proteins. A pin-spotted microarray was used for the DEAL-based protein detection. Each row 
represents a different condition. For each row, the full cocktail of DEAL conjugates (for the 11 assayed 
proteins) was used, with one standard protein was tested per row. Red spots are signal from the standard 
proteins and the green spots alignment reference signals from Cy3-labeled DNA sequence #M’. 
Phospho-VEGFR2 can not be validated because the standard protein is not available. Phospho-VEGFR2 
antibody pairs don’t cross-react with total VEGFR2 and other proteins in the panel. However, 
phospho-VEGFR and phospho-p38 show a low level of background of direct binding between capture 
antibody and detection antibody. (G) Assay data from single and few cell measurements for EGFR. For the 
SCBC assays, EGFR levels are typically within the linear response regime for the calibration curves, which 
implies that a plot of EGFR signal level versus # of cells should be linear, as shown here. Each dot 
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represents an individual experiment, and the red line is fitted to the average protein levels.  
 
Figure SM.III.2 Simulations to account for cell position within the microchamber. The barcode 
interspace is the distance between the cell and the distal barcode stripe. (A) The experimentally 
measured fluorescence intensity ratio versus barcode interspace for 3 proteins indicates a systematic 
error that can be accounted for. (B)-(D) Simulation results. Average barcode intensities are simulated by 
accounting for protein diffusion within the microchamber to the two duplicate barcode stripes (at positions 
L, G, and A for the 3 histograms). Each histogram is the average of 5000 simulations, each with the cell 
located randomly within the microchamber. The blue curves are Gaussian fits. (E) Illustration of barcode 
intensity (position L) versus cell location for three simulations. The yellow dots represent the location of 
the cell in each chamber. The brightness of the barcode corresponds to the signal intensity. The 
chambers yielded averaged signal intensities between 161 and 184. This means that although a strong 
cell location dependence is reflected in the individual barcode intensity variations, the average of the two 
barcode measurements is not influenced by the cell location. (F) Estimation of single cell biological 
coefficient of variation (CV) of U87 EGFRvIII cells for different proteins. The CV of the assay is directly 
adopted from Supplementary Table S3.  
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Table SM.III.1. (top rows) Mean intensity, standard deviation and coefficient of variation (CV) of 
standard proteins in calibration experiments. (bottom rows) Parameters utilized for protein assay 
calibration curves. The calibration curves were well fit by a four-parameter Morgan-Mercer-Flodin (MMF) 
model, which is a common model for sigmoidal or S-shaped growth. Based on this model, the fluorescence 
intensity can be translated into concentration (pg/mL).   
d
d
ab cxy
b x
   
 
  EGFR p-ERK p-p38α p-GSK3α/β p-p70S6K p-mTOR p-Src 
50 ng/ml 803.86±
15.27 
500.16±
46.12 
204.45±
18.92 
720.68±
22.72 
719.11±
17.12 
339.45±
26.08 
804.87±
14.74 
CV 0.02 0.09 0.09 0.03 0.02 0.08 0.02 
10 ng/ml 733.32±8.43
191.47±
11.93 87.40±6.64
321.67±
14.40 
283.54±
14.35 117.64±6.01 
736.16±
18.34 
CV 0.01 0.06 0.08 0.04 0.05 0.05 0.02 
1 ng/ml 269.06±8.83 28.84±3.25 20.80±3.61 61.07±4.62 43.17±3.4 14.35±1.13 
243.66±
10.37 
CV 0.03 0.11 0.17 0.08 0.08 0.08 0.04 
100 pg/ml 67.14±4.3 5.86±0.93 9.74±1.44 7.09±0.85 8.02±0.88 5.29±0.59 52.16±4.66
CV 0.06 0.16 0.15 0.12 0.11 0.11 0.09 
10 pg/ml 22.01±2.14 4.25±0.65 8.86±0.9 5.71±0.91 6.59±0.98 4.87±0.57 19.58±1.62
CV 0.10 0.15 0.10 0.16 0.15 0.12 0.08 
0 12.45±1.5 4.34±0.71 7.2±0.95 5.11±0.69 6.87±0.59 4.43±0.37 8.97±0.86
CV 0.12 0.16 0.13 0.13 0.09 0.08 0.10 
Parameters for Protein Assay Calibration Curves 
 a b c d r 
EGFR 1.230 667.38 1179.21 0.758 0.9999 
p-ERK 3.864 28142.75 884.84 0.970 0.9999 
p-p38α 7.911 11874.57 382.78 0.876 0.9999 
p-GSK3α/β 3.283 7972.09 1234.7 0.861 0.9999 
p-p70S6K 5.808 26921.69 1218.11 0.976 0.9999 
p-mTOR 4.280 101832 562.39 1.103 0.9999 
p-Src 10.618 1161.08 1173.15 0.821 0.9999 

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Supplementary Figures 
 
Supplementary Fig. S1. Comparison of phosphorylation levels by 4 different cell lysis protocols, plus 
a control (E). Protocol D resembles the approach used for the SCBC. All assays used a spot-based DEAL 
chip (Fig. S3) and two representative proteins, p-EGFR (membrane) and p-p70S6K (intracellular) were 
assayed to compare and contrast the lysis protocols. Two cell lysis buffers were used. Cell lysis buffer #1 
was prepared by mixing Cell Lysis Buffer (Cell Signaling, containing 20 mM Tris-HCl, 150 mM NaCl, 1 
mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM -glycerophosphate, 1 
mM Na3VO4, and 1 μg/ml leupeptin), Complete Protease Inhibitor Cocktail (Roche) and Phosphatase 
Inhibitor Cocktail 2 (Sigma). Lysis buffer #2 is suggested by R&D in their phosphoprotein ELISA kits. It 
is similar to the lysis buffer #1, except the addition of 6 M urea. Lysis buffer #2, with the high urea content, 
is considered more effective for protein extraction from the nucleus. The following protocols each used 
~0.5 million cells. (A) After stimulation, cells were washed with cold PBS. The PBS was removed 
completely and 250 μl of lysis buffer #1 was added in the dish. The plate was incubated on ice for 10 min. 
Cells were scraped and the cell lysate was spun for 10 min at 14,000 x g in a cold microfuge. The 
supernant was removed for use. (B) Protocol same as (A) except that cell lysate was sonicated briefly 
before spinning. (C) Protocol same as (A) except using lysis buffer #2. (D) After cell treatment, the cells 
were dissociated with trypsin and EDTA for 5 minutes, centrifuged at 4oC, suspended in cold PBS, and 
re-centrifuged again at 4oC to collect cells. 250 μl of lysis buffer #1 was added in the tube. The tube was 
incubated on ice for 10 minutes, and the cell lysate was spun 10 min at 14,000 x g in a cold microfuge. 
The supernant was removed for use. The results show that the lysis buffer #1 can efficiently extract 
proteins from cells, and that protocol D doesn’t affect the phosphorylation levels of proteins from lysed 
cells and is, in fact, highly effective. (E) The negative control shows no non-specific binding of cell lysate 
to the DNA arrays. No p-EGFR and p-p70S6K conjugates were added. Cell lysate prepared according to 
(A) was added and biotin-labeled detection antibody and streptavidin-labeled cy5 were added to develop 
the assay. Note: The contrast and brightness were equally adjusted for all figures. 
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Supplementary Fig. S2. Representative fluorescence images, and resultant heat maps, from on-chip 
intracellular protein profiling in the model GBM cell lines. The y-axis labels indicate the stimulation 
conditions, and the x-axis labels indicate the numbers of cells per microchamber assay. The barcodes 
shown are from a single barcode assay from a single microchamber containing U87 EGFRvIII PTEN cells 
(A). All images have been equally contrast enhanced to more clearly illustrate which proteins were 
detected. (B) Complete heat maps of cytoplasmic protein profiling in all cell lines and conditions. All heat 
maps have been equally contrast enhanced to better illustrate which proteins were and were not detected. 
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Supplementary Fig. S3. Spot-based platform utilized for multiplex protein assays from large 
numbers of cells, and application in monitoring EGFR phosphorylation, with comparison against 
SCBC data. The spot-based platform is a variant of ELISA, and was also used for characterizing antibody 
cross-reactivities. The sandwich immunoassays are identical to the DEAL-based assays used within the 
SCBC. (A) Layout of DNA spot microarrays. The inset shows a basic unit consisting of 13 DNA spots (#A 
to #M, comprised of the same ssDNA oligomers used for the DNA barcodes). Spot diameters are 150 μm. 
The basic unit is repeated over 6 columns and 50 rows to make a DNA spot array containing 60X50 spots. 
(B) Photograph of a spot-based chip for multiplexed protein measurement from large numbers of cells, 
and for antibody cross-reactivity studies. This 12-well PDMS slab is bonded to the glass slide with the 
pre-printed DNA spot microarrays. Each well has a volume of 50 μl and contains a complete set of 13 
DNA spots for simultaneously assaying the entire panel of proteins.  (C) Spot-based EGFR 
phosphorylation measurements in U87, U87 EGFRvIII and U87 EGFRvIII PTEN cells, under the 
conditions of standard culture, EGF stimulation, and erlotinib (eb) + EGF stimulation. The same numbers 
of cells were lysed in each condition for comparison. As a control, EGFR standard protein was used to 
validate the specificity of the phospho-specific antibodies. (D) Representative fluorescence images of 
on-chip measurements of EGFR phosphorylation in U87 EGFRvIII cells. The numbers in the figure 
represent the number of cells in the chamber. Three phosphorylation sites (Y1173, Y1068 and Y845) were 
examined. All images have been equally contrast enhanced to better illustrate which EGFR 
phosphorylation sites were and were not detected.  
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Supplementary Figure S4.  Graphical representations of the information that is uniquely extracted at the 
single cell level.  All data were collected using the SCBC platform.  Representative error bars, based 
upon the measured standard deviations, are provided. (A) Relative abundance levels of P53, recorded for 0, 
1, 2, and 3 cell experiments. Note that the lowest abundance levels correlate linearly with numbers of cells 
in the chamber, and that a small fraction of cells with high p53 levels begin to dominate the measured 
signal in the 3 cell experiments. (B) Abundance histograms of p-ERK levels measured from single U87 
EGFRvIII PTEN cells. This data is consistent with the data from Fig. 4A - p-Erk levels increase upon EGF 
stimulation, and then decrease back to baseline upon erlotinib + EGF stimulation.  However, the single 
cell data reveal that the erlotinig+EGF stimulated cells exhibit a much more homogeneous behavior than 
do the unstimulated cells  (biological coefficient of variation of 28% versus 57%) . (C-D) Characteristic 
protein-protein correlations. (C) Plot showing a strong correlation between p-p70S6K and p-mTOR in 
U87 EGFRvIII cells, regardless of the numbers of cells in the microchamber, for 1-5 cell experiments 
(note the 0-cell baseline). (D) Plot showing the anticorrelation between p-GSK3 and p-ERK in U87 
EGFRvIII PTEN cells. The listed % values indicate the fraction of cells in a particular quadrant.  
Percentages in black font include 1 and 2 cell data; grey font values include 1-4 cell data. Note that the 1 
and 2 cell experiments exhibit a similarly high level of anticorrelation, but that the anticorrelation begins 
to be masked by population effects once the 3 and 4 cell data is included in the scatter plot.   
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Supplementary Tables 
Supplemental Table S1. Reagents Used. At top are the Sequences and terminal functionalization of 
oligonucleotides. All oligonucleotides were synthesized by Integrated DNA Technology (IDT) and purified 
via high performance liquid chromatography (HPLC). The DNA coding oligomers were pre-tested for 
orthogonality to ensure that cross-hybridization between non-complementary oligomer strands was negligible 
(<1% in photon counts). (4)  Next are listed the antibodies used for the multiplex protein assays. All 
antibody pairs except p-EGFR and p-VEGFR2 were purchased from commercial available ELISA kits 
(R&D systems, DuoSet® Elisa Development Reagents) containing capture antibodies, biotinylated 
detection antibodies and standard proteins. Capture antibodies bind both phosphoryalted and 
unphosphorylated proteins. Biotinylated detection antibodies detect only phosphorylated proteins. 
p-EGFR antibodies specific for phosphorylation of EGFR at Y1173, Y1068 and Y845 were purchased 
from R&D systems as capture antibodies and biotin-labeled EGFR was used as detection antibody. 
p-VEGFR2 (Y1214) capture antibody and biotin-labeled VEGFR2 detection antibody were purchased 
from Abcam. 
 
Name            DNA Sequence Melting Point 
A 5'- AAA AAA AAA AAA AAT CCT GGA GCT AAG TCC GTA-3' 57.9 
A' 5' NH3- AAA AAA AAA ATA CGG ACT TAG CTC CAG GAT-3' 57.2 
B 5'-AAA AAA AAA AAA AGC CTC ATT GAA TCA TGC CTA -3' 57.4 
B' 5' NH3AAA AAA AAA ATA GGC ATG ATT CAA TGA GGC -3' 55.9 
C 5'- AAA AAA AAA AAA AGC ACT CGT CTA CTA TCG CTA -3' 57.6 
C' 5' NH3-AAA AAA AAA ATA GCG ATA GTA GAC GAG TGC -3' 56.2 
D 5'-AAA AAA AAA AAA AAT GGT CGA GAT GTC AGA GTA -3' 56.5 
D' 5' NH3-AAA AAA AAA ATA CTC TGA CAT CTC GAC CAT -3' 55.7 
E 5'-AAA AAA AAA AAA AAT GTG AAG TGG CAG TAT CTA -3' 55.7 
E' 5' NH3-AAA AAA AAA ATA GAT ACT GCC ACT TCA CAT -3' 54.7 
F 5'-AAA AAA AAA AAA AAT CAG GTA AGG TTC ACG GTA -3' 56.9 
F' 5' NH3-AAA AAA AAA ATA CCG TGA ACC TTA CCT GAT -3' 56.1 
G 5'-AAA AAA AAA AGA GTA GCC TTC CCG AGC ATT-3' 59.3 
G' 5' NH3-AAA AAA AAA AAA TGC TCG GGA AGG CTA CTC-3' 58.6 
H 5'-AAA AAA AAA AAT TGA CCA AAC TGC GGT GCG-3' 59.9 
H' 5' NH3-AAA AAA AAA ACG CAC CGC AGT TTG GTC AAT-3' 60.8 
I 5'-AAA AAA AAA ATG CCC TAT TGT TGC GTC GGA-3' 60.1 
I' 5' NH3-AAA AAA AAA ATC CGA CGC AAC AAT AGG GCA-3' 60.1 
J 5'-AAA AAA AAA ATC TTC TAG TTG TCG AGC AGG-3' 56.5 
J' 5' NH3-AAA AAA AAA ACC TGC TCG ACA ACT AGA AGA-3' 57.5 
K 5'-AAA AAA AAA ATA ATC TAA TTC TGG TCG CGG-3' 55.4 
K' 5' NH3-AAA AAA AAA ACC GCG ACC AGA ATT AGA TTA-3' 56.3 
L 5'-AAA AAA AAA AGT GAT TAA GTC TGC TTC GGC-3' 57.2 
L' 5' NH3-AAA AAA AAA AGC CGA AGC AGA CTT AAT CAC-3' 57.2 
M 5'-Cy3-AAA AAA AAA AGT CGA GGA TTC TGA ACC TGT-3' 57.6 
M' 5' NH3-AAA AAA AAA AAC AGG TTC AGA ATC CTC GAC-3' 56.9 
DNA label Antibody source 
A’ Human p-PDGFR (Y751) kit R&D DYC3096 
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B’ Human p-Src (Y419) kit R&D DYC2685 
C’ Human p-mTOR (S2448) kit R&D DYC1665 
D’ Human p-p70S6K (T389) kit R&D DYC896 
E’ Human p-GSK3 (S21/S9) kit R&D DYC2630 
G’ Human p-p38 (T180/Y182) kit R&D DYC869 
H’ Human p-ERK (T202/Y204) kit R&D DYC1825 
I’ Human p-JNK2 (T183/Y185) kit R&D DYC2236 
K’ Human total EGFR kit R&D DYC1854 
L’ Human total P53 kit R&D DYC1043 
Capture antibody: rabbit anti-human p-VEGFR2 (Y1214) Abcam ab31480 
J’ 
Detection antibody: biotin-labeled mouse anti-human VEGFR2 Abcam ab10975 
rabbit anti-human EGFR (Y1173) R&D AF1095 
G’ 
Detection antibody: biotin-labeled goat anti-human EGFR R&D BAF231 
mouse anti-human EGFR (Y1068) R&D MAB3570 
I’ 
Detection antibody: biotin-labeled goat anti-human EGFR R&D BAF231 
rabbit anti-human EGFR (Y845) R&D AF3394 
K’ or L’ 
Detection antibody: biotin-labeled goat anti-human EGFR R&D BAF231 
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Supplemental Table S2. Calculation of signal-to-noise ratio (S/N) in all SCBC measurements. The 
detection of a protein is defined by a S/N >= 2. This S/N was calculated with the signal represented by the 
average values from the duplicate barcode readings from each microchamber, and then computing an 
average over all experiments for a given set of conditions. The noise was the measured background level, 
as estimated from the negative control DNA stripe within each barcode. See Supplementary Table S5-S7 
for averaged values of measured protein levels for each condition (cell lines, stimulation conditions and 
numbers of cells). The following tables show the average S/N of 1-, 2-, 3-, 4-, and 5-cell measurements in 
all cell lines and conditions.   Note: p-VEGFR and p-p38 need correction before S/N calculation. They 
show background signals resulted from binding between surface-immobilized capture antibodies and 
detection antibodies. Such background levels, which can be obtained from zero-cell measurements, should 
be subtracted in cell measurements. 
(1) 
U87  p53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR
1 7 135 2 1 1 4 6 2 2 3 1 
2 10 183 4 1 2 4 6 3 2 3 1 
3 13 194 4 1 2 5 6 4 3 5 1 
4 18 185 5 1 3 5 5 5 2 5 1 
5 29 221 14 2 4 6 7 6 3 4 1 
(2) 
U87 (EGF) p53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR
1 11 162 8 1 3 9 11 12 3 6 1 
2 19 225 11 1 4 10 12 16 4 10 1 
3 31 306 18 2 6 14 14 19 7 12 1 
4 40 263 29 3 5 13 15 17 6 11 1 
5 35 199 26 2 6 12 14 15 7 9 1 
(3) 
U87 
(erlotinib+EGF) 
p53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR
1 5 100 4 1 2 2 3 6 3 4 1 
2 6 123 5 1 3 3 3 7 3 4 1 
3 10 152 7 1 3 3 4 7 4 5 1 
4 17 211 11 2 4 4 4 8 5 6 2 
5 21 176 12 1 3 3 4 9 4 5 1 
(4) 
U87 EGFRvIII  p53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR
1 5 101 3 2 2 4 4 5 6 4 1 
2 6 115 5 3 3 3 4 5 7 4 1 
3 10 157 9 3 5 5 5 7 12 6 1 
4 11 145 10 3 5 6 5 7 12 7 1 
5 16 148 12 4 5 7 6 8 14 8 1 
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(5) 
U87 EGFRvIII  
(EGF) 
p53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR
1 7 179 13 6 10 13 10 15 16 8 2 
2 10 209 20 9 11 17 11 17 21 10 3 
3 14 228 31 9 12 18 11 17 24 11 2 
4 19 226 36 10 12 20 12 18 26 12 3 
5 26 250 44 11 16 26 16 21 32 16 3 
(6) 
U87 EGFRvIII  
(erlotinib+EGF) 
p53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR
1 4 112 9 3 6 4 5 7 10 4 0 
2 7 136 9 3 7 6 7 9 12 5 1 
3 9 146 11 4 8 7 8 9 13 5 1 
4 13 143 12 3 8 8 8 11 14 7 1 
5 17 152 16 4 9 10 9 12 17 8 1 
(7) 
U87 EGFRvIII  
PTEN 
p53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR
1 9 98 6 2 3 6 10 2 3 4 2 
2 11 112 7 2 3 7 9 2 2 4 1 
3 21 171 9 2 4 8 12 3 3 5 1 
4 25 202 12 2 5 10 12 3 4 5 2 
5 26 199 12 2 5 10 12 3 4 6 1 
(8) 
U87 EGFRvIII 
PTEN (EGF) 
p53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR
1 13 130 14 1 12 11 12 10 8 11 1 
2 21 221 26 2 23 19 18 14 15 18 1 
3 21 195 19 2 17 14 12 10 11 13 1 
4 26 230 21 2 17 14 12 10 11 13 1 
5 38 261 25 3 20 16 14 13 13 14 1 
(9) 
U87 EGFRvIII 
PTEN (erlotinib + 
EGF) 
p53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR
1 6 147 11 1 2 4 8 1 1 4 1 
2 10 147 12 1 2 3 7 1 1 4 1 
3 18 171 15 1 2 3 7 1 1 4 1 
4 19 180 14 1 3 4 7 1 1 4 1 
5 23 164 13 1 4 4 6 1 1 4 1 
 

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Supplemental Table S3. Mean intensity and standard deviation (std, red font) for proteins assayed from 
U87, U87 EGFRvIII and U87 EGFRvIII PTEN cells, as a function of # of cells, and under the different 
conditions.  At the bottom (blue font) is presented the mean fold change and standard error of protein and 
phosphoprotein levels. For calculating the mean fold change values, unperturbed U87 was set as the base 
line, and mean fold changes of protein levels in the cell lines and conditions were calculated. This mean 
fold change was calculated as follows: For a microchamber i containing n cells, the fluorescence levels 
recorded from the two barcode assays for a given protein  were averaged to yield i,n. The fluorescence 
intensity for , averaged over all 0-cell measurements, was subtracted as background: )( 0,  ni . This 
value was then normalized against the background-subtracted, fluorescence levels of  averaged over all n 
cell measurements for unperturbed U87: 1, 0 , 87( ) ( ) 1i n n U      . These values for the fold-change in 
the levels of each assayed protein for each microchamber were then averaged over all microchambers 
containing 2-5 cells. Standard error of median (SEM) is calculated accordingly. Number of measurements 
is also listed. 
 
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 403.81 2.24 2.29 14.87 2.52 1.20 11.48 3.14 0.65 2.29 1.77 3.04 1.85 
1 382.03 19.80 384.80 19.94 3.49 3.78 22.47 2.84 16.48 5.42 5.01 7.51 2.65 
2 396.52 28.69 544.72 26.87 3.88 6.11 24.01 2.98 18.19 10.01 7.28 10.38 3.63 
3 423.98 40.12 595.11 28.03 4.03 7.10 27.17 3.06 18.82 12.95 7.70 13.83 3.16 
4 402.42 64.10 664.33 32.98 4.80 10.99 30.06 3.59 18.55 16.21 7.87 16.90 1.93 
5 373.08 92.42 706.23 58.71 5.63 13.76 31.76 3.20 22.43 18.16 10.15 13.87 3.19 
U87 
 
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 415.70 1.28 3.61 24.41 2.39 0.83 7.22 2.65 0.73 1.31 1.56 1.24 0.47 
1 420.95 28.64 418.24 46.37 3.23 7.20 31.43 2.59 29.34 31.99 8.08 15.44 2.53 
2 424.75 48.68 578.54 51.67 3.55 10.61 33.95 2.57 31.12 40.95 10.65 25.94 3.55 
3 414.15 73.76 726.12 67.83 4.89 13.63 39.64 2.37 34.41 45.93 16.56 28.78 3.46 
4 413.53 118.79 773.29 110.58 8.35 15.94 44.71 2.94 43.29 50.62 19.06 32.03 2.83 
5 424.47 136.49 780.69 126.49 8.63 21.94 52.65 3.93 56.73 60.23 26.76 35.21 3.19 
U87 
+  
EGF 
 
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 384.05 2.11 3.13 29.50 2.20 1.34 10.18 0.88 0.55 2.76 1.70 2.14 0.80 
1 384.42 18.67 374.74 45.24 5.53 8.64 19.45 3.73 12.02 22.08 10.51 13.21 5.56 
2 381.35 25.94 495.02 51.43 5.32 10.16 21.87 4.02 12.81 26.20 12.08 15.90 5.14 
3 384.71 39.22 566.42 56.64 5.57 11.42 22.58 3.74 13.43 26.16 13.15 18.84 5.29 
4 386.49 54.69 683.23 66.43 5.35 12.32 22.77 3.24 14.44 27.33 15.18 20.87 5.12 
5 380.24 87.64 733.72 79.67 5.16 13.39 23.37 4.16 16.80 35.69 17.91 22.45 6.09 
U87 
+  
EGF 
+ 
eb 
 
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 30.30 1.32 0.76 5.64 1.57 0.74 2.37 3.57 0.51 0.90 0.22 1.52 1.15 
1 38.66 14.51 123.07 7.29 1.36 1.82 10.41 1.33 5.47 2.65 2.54 7.18 1.40 
2 51.31 12.62 96.37 13.87 1.48 2.88 6.75 1.35 5.36 5.19 4.88 9.10 1.72 
U87 
std 
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3 57.36 20.20 118.85 12.29 1.31 4.22 9.88 1.47 9.00 4.15 4.28 8.34 1.75 
4 35.00 39.63 97.98 16.35 1.00 4.36 6.69 1.58 7.55 11.40 5.14 10.84 1.07 
5 35.53 50.58 101.77 25.57 1.24 9.03 10.58 1.79 6.46 11.33 7.12 6.87 1.92 
 
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 22.30 0.63 0.83 5.19 0.81 0.29 1.40 2.29 0.24 0.68 0.13 0.89 0.24 
1 42.69 12.96 145.74 15.27 1.41 4.91 13.76 1.48 11.19 9.84 4.43 8.51 1.33 
2 48.00 34.25 116.05 18.47 1.61 3.06 11.74 1.63 9.89 9.85 4.66 12.94 2.42 
3 32.29 28.70 71.26 32.32 2.21 4.13 7.43 1.32 8.52 9.00 10.12 7.05 1.50 
U87 
+ 
EGF 
std 
4 18.47 43.52 32.99 16.56 2.87 4.75 15.57 1.27 8.40 11.44 7.10 9.16 2.22  
5 38.37 41.30 33.32 46.91 0.89 15.81 16.73 2.26 21.09 17.43 10.40 7.34 2.54  
 
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 14.50 1.06 0.93 6.78 0.49 0.22 2.86 0.40 0.37 1.09 0.12 0.44 0.29 
1 13.10 5.26 70.17 9.73 0.94 1.35 2.71 1.15 2.40 3.08 2.63 4.51 1.00 
2 10.21 10.18 79.79 11.04 0.76 1.32 2.94 1.17 1.75 3.18 2.29 4.33 0.48 
3 10.50 25.71 94.81 10.24 1.00 1.68 2.37 1.06 2.22 2.63 3.49 4.92 0.41 
4 11.34 25.70 72.01 6.13 1.16 1.41 2.67 0.86 2.48 6.37 2.82 6.69 0.72 
5 11.26 16.17 21.01 7.68 1.72 0.91 3.03 0.92 2.97 5.85 7.69 3.73 1.15 
U87 
+ 
EGF 
+ 
eb 
(std) 
  
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 378.74 3.05 3.40 26.61 3.03 1.72 13.04 1.29 1.21 3.34 1.68 2.71 1.07 
1 388.54 21.66 478.11 42.73 9.52 10.69 29.73 4.75 16.71 23.13 26.61 19.04 5.27 
2 386.66 27.32 567.97 52.53 12.53 14.39 30.08 4.94 17.91 26.31 35.86 21.50 5.28 
3 382.84 43.24 688.07 66.40 14.62 20.55 36.38 4.38 21.24 29.40 50.41 24.61 4.89 
4 387.14 57.77 735.43 76.10 15.73 23.22 41.96 5.06 24.66 36.88 60.61 34.79 5.98 
5 373.04 88.48 802.16 94.07 20.86 28.07 52.42 5.44 30.10 45.04 73.66 42.85 5.18 
U87 
EGFRVIII
 
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 397.04 3.03 4.36 24.97 2.82 2.22 13.49 1.01 0.93 3.73 1.81 2.89 1.10 
1 413.40 19.25 476.95 59.57 15.50 26.92 47.99 2.66 25.87 39.32 43.89 22.05 5.01 
2 411.70 27.59 579.62 81.44 24.98 30.33 61.07 2.77 29.64 46.46 58.61 28.30 7.42 
3 416.12 43.10 721.14 122.76 29.63 37.57 71.37 3.16 34.59 54.16 75.14 33.90 7.88 
4 421.36 63.40 762.14 144.66 33.76 41.02 79.86 3.37 40.71 59.80 89.14 41.76 8.78 
5 398.36 83.97 801.47 164.69 36.45 49.82 95.95 3.20 51.10 67.18 103.44 50.34 9.11 
U87 
EGFRVIII
+ 
EGF 
 
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 384.74 2.75 3.95 26.24 2.81 1.65 11.84 1.43 1.35 2.69 1.68 3.19 1.05 
1 399.74 17.94 453.10 61.89 12.45 24.27 29.58 4.05 20.64 26.95 39.78 15.23 1.77 
2 400.97 30.28 567.72 64.22 12.49 31.19 36.65 4.17 27.59 36.97 50.72 22.34 3.08 
3 411.64 42.38 673.86 78.75 18.90 36.67 43.97 4.60 35.59 42.62 61.40 23.60 3.56 
4 414.72 67.17 724.37 85.05 13.69 43.11 53.92 5.08 38.90 56.30 73.36 33.72 5.49 
5 414.24 87.63 783.60 106.46 20.06 47.88 63.99 5.14 47.02 60.55 85.44 38.61 4.64 
U87 
EGFRVIII
+ 
EGF 
+  
eb 
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cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 16.35 1.47 0.78 7.77 0.90 0.70 4.44 0.90 0.42 2.28 0.25 0.59 0.69 
1 13.32 5.60 89.41 6.61 3.59 3.10 4.60 1.19 3.06 3.01 6.96 4.17 2.06 
2 9.22 7.64 83.71 10.94 3.51 4.71 7.00 2.07 2.99 4.50 8.36 4.64 1.78 
3 16.46 9.58 36.77 12.41 3.27 4.57 6.39 1.48 3.66 4.66 7.60 4.85 1.55 
4 19.57 6.24 54.94 17.45 6.38 5.43 5.20 1.84 4.14 5.16 8.15 7.97 2.17 
5 12.94 16.61 13.30 14.15 5.20 3.75 9.95 1.67 3.26 5.58 8.89 12.37 1.09 
U87 
EGFRVIII
(std) 
 
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 21.09 1.35 0.78 6.59 0.73 0.88 3.19 0.30 0.43 1.86 0.11 1.17 0.70 
1 33.42 5.13 84.21 17.17 6.39 6.09 14.42 1.57 7.54 10.47 10.76 9.44 2.61 
2 24.88 5.66 53.66 21.92 9.04 7.21 19.65 1.66 10.65 17.12 15.11 17.02 5.72 
3 25.84 6.22 46.98 50.42 7.44 8.05 20.51 1.87 9.30 14.76 20.83 18.29 6.57 
4 28.09 8.78 42.57 46.16 12.30 8.45 26.53 2.33 15.34 13.77 21.48 18.16 6.23 
U87 
EGFRVIII
+ 
EGF 
(std) 
5 26.02 20.46 68.48 56.14 5.66 7.59 29.04 1.37 18.14 19.27 37.54 28.27 10.53  
 
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 20.46 0.81 1.16 8.90 0.68 0.75 2.93 0.73 0.59 1.34 0.15 0.74 0.36 
1 11.74 5.03 49.82 15.18 8.12 7.17 7.58 2.80 7.78 7.34 6.76 7.33 1.52 
2 13.41 7.39 56.69 8.32 9.91 5.18 9.58 2.55 9.48 10.18 11.16 7.99 2.90 
3 21.42 9.16 41.18 18.06 10.82 12.24 15.43 3.07 11.44 9.91 15.22 8.22 2.28 
4 19.28 6.26 37.52 20.58 7.75 16.65 21.53 3.57 14.95 21.57 21.22 13.80 3.44 
5 18.90 16.79 50.15 36.58 5.99 14.13 15.25 3.25 13.60 21.34 19.09 13.68 5.17 
U87 
EGFRVIII
+ 
EGF 
+  
eb 
(std) 
 
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 384.61 3.25 2.88 20.10 3.44 1.10 12.88 0.87 0.96 1.41 1.73 3.47 0.36 
1 381.18 27.33 283.56 37.96 5.83 7.53 30.75 2.89 27.92 7.15 7.32 11.83 4.41 
2 369.80 36.31 363.47 42.77 5.58 8.36 34.88 3.26 30.67 7.33 7.55 12.98 4.03 
3 368.64 56.97 466.70 46.03 6.21 10.66 35.75 2.73 31.46 7.52 9.04 14.48 3.82 
4 383.82 68.22 545.53 52.54 6.74 12.67 39.44 2.71 32.61 9.10 10.76 14.48 4.27 
5 382.19 75.71 574.20 54.77 6.96 13.37 41.22 2.88 33.99 9.13 11.93 17.07 3.13 
U87 
EGFRVIII
PTEN 
 
 
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 385.52 2.86 3.87 26.30 2.72 1.53 9.63 0.80 0.72 2.58 1.74 1.90 0.58 
1 412.33 25.18 262.04 54.41 2.71 24.29 32.12 2.01 23.84 19.58 15.64 23.02 2.24 
2 400.03 34.14 360.20 69.42 3.84 38.11 39.96 1.63 28.92 22.94 24.77 29.28 1.79 
3 395.77 49.89 472.01 73.00 4.74 41.88 43.11 2.43 30.30 25.24 27.60 31.28 1.90 
4 398.65 66.69 596.30 81.81 4.69 43.17 44.88 2.59 31.01 27.00 27.42 32.67 2.31 
5 390.22 90.98 623.85 85.15 6.44 46.63 47.75 2.39 32.39 31.21 30.47 33.48 2.39 
U87 
EGFRVIII
PTEN 
+ 
EGF 
 
 
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 369.50 1.75 4.97 23.63 2.50 1.05 8.19 2.84 1.19 2.43 1.62 1.85 0.85 U87 
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1 372.30 13.11 326.30 48.22 2.92 3.61 16.24 2.22 16.72 3.06 2.76 8.55 1.81 
2 371.09 27.80 415.36 57.37 3.17 5.88 17.46 2.82 19.43 3.31 3.88 10.83 2.75 
3 372.73 50.64 494.14 65.81 3.17 7.02 17.99 2.88 21.24 3.94 3.52 12.55 1.94 
4 363.36 61.77 573.10 66.83 4.26 8.84 20.16 3.19 22.26 4.11 3.52 13.05 2.78 
5 365.16 91.42 641.41 73.24 5.86 14.10 22.46 3.92 25.08 4.76 4.67 16.52 3.45 
EGFRVIII
PTEN 
+ 
EGF 
+  
eb 
 
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 20.64 1.09 0.80 2.70 1.19 0.51 2.29 0.52 0.89 0.71 0.14 0.72 0.25 
1 47.40 11.84 61.25 13.69 2.92 6.38 9.14 1.54 11.50 2.99 3.31 5.43 2.90 
2 45.83 14.26 135.31 15.15 2.23 6.85 12.06 1.78 15.94 3.09 3.91 7.61 1.94 
3 55.28 21.83 108.94 16.52 1.62 5.25 12.18 1.70 9.85 3.30 3.84 6.17 2.89 
4 52.66 26.28 103.55 10.65 2.51 9.18 13.24 1.43 10.44 4.45 6.83 5.92 2.34 
5 49.54 22.53 137.77 14.42 2.32 7.13 11.18 1.64 12.87 3.19 4.32 6.29 2.60 
U87 
EGFRVIII
PTEN 
(std) 
 
 
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 21.54 0.90 1.79 5.88 1.03 1.02 1.72 0.51 0.42 1.29 0.14 0.95 0.33 
1 16.96 5.31 54.66 13.53 1.43 9.91 10.23 1.19 7.98 3.09 5.83 5.21 1.50 
2 23.34 7.01 106.16 11.03 1.33 11.46 5.57 1.01 5.73 2.98 8.03 8.10 1.26 
3 16.90 16.34 77.90 12.78 2.22 11.49 5.16 1.65 7.67 3.63 7.30 6.68 1.05 
4 13.22 12.60 77.81 13.57 0.96 8.72 7.80 2.00 7.60 4.86 8.45 8.13 1.48 
5 23.63 19.13 39.10 16.58 1.66 12.37 3.93 1.53 6.16 5.53 6.59 8.37 1.25 
U87 
EGFRVIII
PTEN 
+ 
EGF 
(std) 
 
cell ref P53 EGFR p-VEGFR p-JNK2 p-ERK p-p38 control p-GSK3 p-p70S6K p-mTOR p-Src p-PDGFR  
0 25.19 0.94 3.42 6.46 0.77 0.47 2.23 2.14 1.54 0.77 0.20 0.81 0.53 
1 23.68 7.16 59.41 11.59 1.16 2.06 4.56 0.93 3.19 1.66 1.07 3.88 1.07 
2 33.84 13.34 73.28 16.67 1.30 4.60 5.27 1.05 3.71 0.87 2.28 4.04 1.53 
3 23.88 10.81 62.81 15.33 1.25 5.13 6.02 0.67 3.60 1.76 1.04 3.05 1.02 
4 32.82 14.57 65.15 12.98 1.48 4.58 6.64 1.01 5.87 1.67 1.13 4.61 1.70 
5 33.56 22.56 44.35 12.00 2.16 9.65 6.41 1.01 5.02 1.44 1.59 6.96 1.62 
U87 
EGFRVIII
PTEN 
+ 
EGF 
+ 
eb 
(std) 
 
Mean Fold Change of Protein & Phosphoprotein Levels 
Mean fold change Reference P53 EGFR p-VEGFR p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src 
# of 
Measurements
U87 (EGF) 0.06 0.78 0.12 1.94 0.89 1.12 1.05 3.34 1.35 1.93 42 
U87 (Erlotinib+EGF) -0.05 -0.07 -0.04 0.89 0.55 -0.20 -0.28 1.38 0.97 0.65 52 
U87 EGFRvIII -0.04 -0.05 0.10 1.32 1.56 0.54 0.12 1.70 6.69 1.63 55 
U87 EGFRvIII (EGF) 0.03 -0.03 0.13 4.60 4.09 2.76 0.93 3.74 11.05 2.31 80 
U87 EGFRvIII 
(Erlotinib+EGF) 
0.02 0.02 0.09 2.21 4.31 1.15 0.83 2.97 8.90 1.43 74 
U87 EGFRvIII PTEN -0.04 0.08 -0.24 0.48 0.27 0.53 0.64 -0.40 0.21 0.16 83 
U87 EGFRvIII PTEN 
(EGF) 
-0.01 0.15 -0.24 2.22 5.28 1.19 0.61 1.25 3.15 2.10 76 
 25
U87 EGFRvIII PTEN 
(Erlotinib+EGF) 
-0.07 0.04 -0.19 1.53 -0.04 -0.31 0.09 -0.87 -0.63 0.12 63 
Standard Error of Protein & Phosphoprotein Levels 
Standard Error of 
Median (SEM) 
Reference P53 EGFR p-VEGFR p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src 
 
U87 (EGF) 0.03 0.21 0.04 0.59 0.23 0.22 0.16 0.48 0.38 0.53  
U87 (Erlotinib+EGF) 0.02 0.10 0.03 0.32 0.15 0.07 0.04 0.22 0.23 0.24  
U87 EGFRvIII 0.02 0.07 0.03 0.38 0.25 0.14 0.06 0.25 0.88 0.36  
U87 EGFRvIII (EGF) 0.02 0.06 0.02 0.78 0.40 0.29 0.12 0.40 1.17 0.47  
U87 EGFRvIII 
(Erlotinib+EGF) 
0.02 0.07 0.02 0.44 0.46 0.18 0.12 0.33 0.97 0.31 
 
U87 EGFRvIII PTEN 0.02 0.09 0.03 0.24 0.16 0.13 0.10 0.06 0.15 0.17  
U87 EGFRvIII PTEN 
(EGF) 
0.02 0.08 0.03 0.45 0.55 0.15 0.08 0.17 0.42 0.41 
 
U87 EGFRvIII PTEN 
(Erlotinib+EGF) 
0.02 0.09 0.04 1.16 0.20 0.10 0.06 0.04 0.08 0.31 
 
            

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Supplemental Table S4. Correlation coefficients of cytoplasmic proteins measured by SCBC in all 
cell lines and conditions. Correlation coefficients were calculated based on 1-2 cells. The cut-off for 
correlation and anti-correlation is 0.4 and -0.4, respectively, and red font is used to indicate the 
above-threshold correlations, which was drawn in the correlation maps (shown in red in the following 
tables). The number of measurements is shown after the table. The proteins shown in blue are below the 
detection limit (S/N<2).   
 p-JNK2 p53 EGFR p-VEGFR p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src 
p-JNK2 1.00 0.05 0.24 0.14 0.17 0.08 0.09 0.16 0.14 0.41 
p53  1.00 0.50 0.34 0.16 0.05 0.02 0.04 -0.07 0.10 
EGFR   1.00 0.65 0.57 0.20 0.27 0.44 0.14 0.07 
p-VEGFR    1.00 0.53 0.35 0.49 0.39 0.25 -0.18 
p-ERK     1.00 0.32 0.40 0.70 0.37 0.03 
p-p38      1.00 0.72 0.32 0.56 0.00 
p-GSK3       1.00 0.44 0.61 -0.19 
p-p70S6K        1.00 0.61 0.10 
p-mTOR         1.00 -0.01 
p-Src          1.00 
U87 
(63 measurements)
 p-JNK2 p53 EGFR p-VEGFR p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src 
p-JNK2 1.00 0.16 0.26 0.16 -0.09 0.23 0.24 0.02 0.11 0.19 
p53  1.00 0.50 0.05 0.39 0.37 0.24 0.51 0.23 0.31 
EGFR   1.00 -0.12 0.44 0.46 0.20 0.61 0.03 0.51 
p-VEGFR    1.00 -0.04 -0.13 0.04 -0.11 0.32 0.03 
p-ERK     1.00 0.31 0.12 0.52 0.12 0.40 
p-p38      1.00 0.80 0.71 0.39 0.32 
p-GSK3       1.00 0.54 0.46 0.27 
p-p70S6K        1.00 0.35 0.47 
p-mTOR         1.00 0.34 
p-Src          1.00 
U87 
+ 
EGF 
(54 measurements)
 
 p-JNK2 p53 EGFR p-VEGFR p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src 
p-JNK2 1.00 0.15 0.28 0.36 0.29 0.00 -0.11 -0.04 0.20 0.46 
p53  1.00 0.58 0.41 0.37 0.33 0.10 0.42 0.27 0.30 
EGFR   1.00 0.60 0.34 0.22 0.06 0.27 0.21 0.50 
p-VEGFR    1.00 0.36 0.16 -0.13 0.22 0.36 0.66 
p-ERK     1.00 0.27 0.07 0.35 0.29 0.34 
p-p38      1.00 0.59 0.62 0.20 0.13 
p-GSK3       1.00 0.51 0.16 -0.06 
p-p70S6K        1.00 0.46 0.22 
p-mTOR         1.00 0.47 
p-Src          1.00 
U87 
+ 
EGF 
+ 
eb 
(62 measurements)
 p-JNK2 p53 EGFR p-VEGFR p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src 
p-JNK2 1.00 0.10 0.08 0.18 0.33 0.17 0.16 0.22 0.39 0.23 
p53  1.00 0.65 0.51 0.50 0.09 0.19 0.30 0.19 0.35 
EGFR   1.00 0.55 0.39 -0.04 0.06 0.21 0.18 0.24 
U87 EGFRvIII
(68 measurements)
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p-VEGFR    1.00 0.41 0.15 0.30 0.26 0.39 0.37 
p-ERK     1.00 0.17 0.27 0.43 0.40 0.41 
p-p38      1.00 0.74 0.66 0.18 0.32 
p-GSK3       1.00 0.64 0.31 0.32 
p-p70S6K        1.00 0.52 0.44 
p-mTOR         1.00 0.36 
p-Src          1.00 
 p-JNK2 p53 EGFR p-VEGFR p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src 
p-JNK2 1.00 0.46 0.42 0.48 0.20 0.32 0.31 0.18 0.23 0.19 
p53  1.00 0.71 0.68 0.43 0.57 0.28 0.40 0.60 0.35 
EGFR   1.00 0.47 0.34 0.41 0.12 0.11 0.46 0.14 
p-VEGFR    1.00 0.58 0.66 0.56 0.47 0.57 0.54 
p-ERK     1.00 0.73 0.74 0.36 0.54 0.59 
p-p38      1.00 0.61 0.34 0.60 0.68 
p-GSK3       1.00 0.49 0.52 0.71 
p-p70S6K        1.00 0.71 0.41 
p-mTOR         1.00 0.51 
p-Src          1.00 
U87 EGFRvIII
+ 
EGF 
(72 measurements)
 p-JNK2 p53 EGFR p-VEGFR p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src 
p-JNK2 1.00 -0.03 0.08 0.02 -0.22 0.04 0.20 -0.20 0.14 -0.09 
p53  1.00 0.72 0.43 0.47 0.44 0.30 0.40 0.53 0.36 
EGFR   1.00 0.17 0.29 0.32 0.24 0.27 0.57 0.31 
p-VEGFR    1.00 0.33 0.16 0.22 0.11 0.21 0.22 
p-ERK     1.00 0.59 0.28 0.59 0.31 0.77 
p-p38      1.00 0.56 0.77 0.42 0.50 
p-GSK3       1.00 0.59 0.45 0.14 
p-p70S6K        1.00 0.30 0.46 
p-mTOR         1.00 0.39 
p-Src          1.00 
U87 EGFRvIII
+ 
EGF 
+ 
eb 
(58 measurements)
 
 p-JNK2 p53 EGFR p-VEGFR p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src 
p-JNK2 1.00 0.19 0.03 0.22 -0.18 -0.12 0.07 0.01 -0.16 -0.13 
p53  1.00 0.31 0.31 0.16 -0.01 -0.08 -0.18 0.22 -0.01 
EGFR   1.00 0.09 -0.06 -0.03 0.13 -0.10 0.15 -0.05 
p-VEGFR    1.00 0.01 0.00 0.28 0.28 -0.07 -0.33 
p-ERK     1.00 -0.13 -0.51 -0.08 0.11 0.04 
p-p38      1.00 0.54 0.42 0.15 0.26 
p-GSK3       1.00 0.55 0.17 0.14 
p-p70S6K        1.00 0.26 0.12 
p-mTOR         1.00 0.54 
p-Src          1.00 
U87 EGFRvIII PTEN
(72 measurements) 
 p-JNK2 p53 EGFR p-VEGFR p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src 
p-JNK2 1.00 0.34 0.16 0.27 0.30 0.36 0.39 0.23 0.34 0.29 
p53  1.00 0.32 0.61 0.32 0.44 0.44 0.29 0.46 0.57 
U87 EGFRvIII PTEN
+ 
EGF 
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EGFR   1.00 0.33 0.26 0.25 0.03 0.18 0.28 0.13 
p-VEGFR    1.00 0.14 0.42 0.29 0.34 0.30 0.57 
p-ERK     1.00 0.36 0.53 0.29 0.75 0.48 
p-p38      1.00 0.67 0.52 0.48 0.31 
p-GSK3       1.00 0.38 0.54 0.28 
p-p70S6K        1.00 0.41 0.30 
p-mTOR         1.00 0.65 
p-Src          1.00 
(82 measurements) 
 p-JNK2 p53 EGFR p-VEGFR p-ERK p-p38 p-GSK3 p-p70S6K p-mTOR p-Src 
p-JNK2 1.00 0.24 0.10 -0.02 0.01 0.29 0.24 0.10 0.07 0.04 
p53  1.00 0.62 0.46 0.27 0.07 0.15 0.09 0.15 0.33 
EGFR   1.00 0.54 -0.03 -0.14 0.11 -0.11 0.06 0.49 
p-VEGFR    1.00 -0.32 -0.47 -0.08 -0.15 -0.04 0.33 
p-ERK     1.00 0.52 0.25 0.32 0.43 -0.02 
p-p38      1.00 0.50 0.39 0.40 -0.10 
p-GSK3       1.00 0.21 0.40 -0.13 
p-p70S6K        1.00 0.22 -0.04 
p-mTOR         1.00 0.01 
p-Src          1.00 
U87 EGFRvIII PTEN
+ 
EGF 
+ 
eb 
(73 measurements) 

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